{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:45:39Z","timestamp":1792680339191,"version":"4.5.0"},"reference-count":46,"publisher":"American Medical Association (AMA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"abstract":"\n Importance<\/jats:title>\n Anti-CD20 biologics are widely used as disease-modifying therapy (DMT) for relapsing-remitting multiple sclerosis (RRMS), but recent reports have raised concerns about an increased risk of inflammatory bowel disease (IBD) during treatment. This study aimed to assess treatment-associated IBD risk in individuals with RRMS.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare the risk of new-onset IBD across different therapies for RRMS and relative to the general population.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This was a population-based cohort study conducted in Sweden. Through the Swedish MS register, initiations of rituximab, natalizumab, dimethyl fumarate, and fingolimod were identified between January 1, 2011, and December 31, 2023, in individuals with RRMS aged 18 to 55 years with at least 10 years of lookback time (5 years for dispensed drugs) and no evidence of previous IBD. These initiations were matched with general population comparator episodes selected from the Swedish population.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Rituximab, comparator DMTs (natalizumab, dimethyl fumarate, fingolimod), or general population comparator.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n \n New-onset IBD, defined as 2 or more records on separate dates with the\n International Statistical Classification of Diseases and Related Health Problems<\/jats:italic>\n ,\n Tenth Revision<\/jats:italic>\n , codes K50 (Crohn disease), K51 (ulcerative colitis), and\/or K52.3 (indeterminate colitis).\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among the 13\u202f748 therapy episodes (6481 rituximab, 2976 natalizumab, 2767 dimethyl fumarate, 1524 fingolimod) in 9251 individuals (range in mean ages of the exposure groups, 35-38 years) and 61\u202f065 matched general population episodes, 164 IBD events occurred during follow-up (40 with rituximab, 4 with comparator DMTs, and 120 in the general population). The crude incidence rate of IBD was 110 (95% CI, 76-147) per 100\u202f000 person-years for rituximab, 13 (95% CI, 3-30) for the comparator DMTs, and 41 (95% CI, 34-48) for the general population. After adjustment for demographics and MS characteristics, the hazard ratio for the comparator DMTs vs rituximab was 0.10 (95% CI, 0.04-0.22). In the rituximab group, 62% of IBD events were classified as Crohn disease compared with 29% in the general population. The number needed to harm for rituximab vs the comparator DMTs was 131 (95% CI, 93-228) at 5 years, after full adjustment.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Results of this cohort study show that rituximab was associated with an increased risk of IBD compared with other modern MS therapies, after adjustment for differences in characteristics at therapy start. Clinicians and individuals with MS should consider IBD risk in treatment decisions and remain vigilant for gastrointestinal symptoms during anti-CD20 therapy.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaneurol.2026.3439","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:30:16Z","timestamp":1792679416000},"source":"Crossref","is-referenced-by-count":0,"title":["Risk of Inflammatory Bowel Disease After Anti-CD20 Treatment in Multiple Sclerosis"],"prefix":"10.1001","author":[{"given":"Sandra","family":"Kallin","sequence":"first","affiliation":[{"name":"Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden"},{"name":"Department of Neurology, Danderyd Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Svenningsson","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden"},{"name":"Department of Neurology, Danderyd Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Ol\u00e9n","sequence":"additional","affiliation":[{"name":"Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden"},{"name":"Sachs\u2019 Children and Youth Hospital, Stockholm South General Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Hedin","sequence":"additional","affiliation":[{"name":"Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden"},{"name":"Centre for Digestive Health, Department of Gastroenterology, Dermatovenereology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Lycke","sequence":"additional","affiliation":[{"name":"Institute of Neuroscience and Physiology, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden"},{"name":"Sahlgrenska University Hospital, Department of Neurology, Region V\u00e4stra G\u00f6taland, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Alping","sequence":"additional","affiliation":[{"name":"Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"issue":"10130","key":"noi260062r1","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple sclerosis.","volume":"391","author":"Thompson","year":"2018","journal-title":"Lancet"},{"issue":"7","key":"noi260062r2","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"issue":"3","key":"noi260062r3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab vs interferon beta-1a in relapsing multiple sclerosis.","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"noi260062r4","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab vs teriflunomide in multiple sclerosis.","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"noi260062r5","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1001\/jamaneurol.2017.4011","article-title":"Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis.","volume":"75","author":"Granqvist","year":"2018","journal-title":"JAMA Neurol"},{"issue":"8","key":"noi260062r6","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1056\/NEJMoa2201904","article-title":"Ublituximab vs teriflunomide in relapsing multiple sclerosis.","volume":"387","author":"Steinman","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"noi260062r7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/ane.12963","article-title":"Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden\u2014outlier or predecessor?","volume":"138","author":"Berntsson","year":"2018","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"noi260062r8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies.","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol"},{"issue":"7","key":"noi260062r9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia.","volume":"1","author":"Barmettler","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"8","key":"noi260062r10","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16331","article-title":"Hypogammaglobulinemia during rituximab treatment in multiple sclerosis: a Swedish cohort study.","volume":"31","author":"Hallberg","year":"2024","journal-title":"Eur J Neurol"},{"issue":"3","key":"noi260062r11","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200211","article-title":"Multiple sclerosis, rituximab, hypogammaglobulinemia, and risk of infections.","volume":"11","author":"Langer-Gould","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"14","key":"noi260062r12","doi-asserted-by":"publisher","first-page":"e1999","DOI":"10.1212\/WNL.0000000000010380","article-title":"Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study.","volume":"95","author":"Bar-Or","year":"2020","journal-title":"Neurology"},{"issue":"5","key":"noi260062r13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.11497","article-title":"Factors associated with serological response to SARS-CoV-2 vaccination in patients with multiple sclerosis treated with rituximab.","volume":"5","author":"Tolf","year":"2022","journal-title":"JAMA Netw Open"},{"key":"noi260062r14","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104763","article-title":"Anti-CD20 monoclonal antibody (mAb) therapy and colitis: a case series and review.","volume":"75","author":"Tolaymat","year":"2023","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"noi260062r15","doi-asserted-by":"publisher","first-page":"447","DOI":"10.20524\/aog.2021.0582","article-title":"Ocrelizumab-induced inflammatory bowel disease\u2013like illness characterized by esophagitis and colitis.","volume":"34","author":"Barnes","year":"2021","journal-title":"Ann Gastroenterol"},{"key":"noi260062r16","article-title":"Ocrelizumab-induced severe colitis.","volume":"2020","author":"Lee","year":"2020","journal-title":"Case Rep Gastrointest Med"},{"issue":"10","key":"noi260062r17","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1177\/13524585231195854","article-title":"Immune-mediated colitis associated with ocrelizumab: a new safety risk.","volume":"29","author":"Kim","year":"2023","journal-title":"Mult Scler"},{"key":"noi260062r18","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1530438","article-title":"Ocrelizumab-induced colitis-critical review and case series from a Romanian cohort of MS patients.","volume":"16","author":"Voda","year":"2025","journal-title":"Front Neurol"},{"issue":"3","key":"noi260062r19","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1177\/13524585231205964","article-title":"A closer look at reported colitis in association with multiple sclerosis treatments.","volume":"30","author":"Porwal","year":"2024","journal-title":"Mult Scler"},{"issue":"2","key":"noi260062r20","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1177\/13524585241303479","article-title":"Ofatumumab-associated colitis: a case report.","volume":"31","author":"Patel","year":"2025","journal-title":"Mult Scler"},{"issue":"1","key":"noi260062r21","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.cgh.2019.03.027","article-title":"De novo colitis associated with rituximab in 21 patients at a tertiary center.","volume":"18","author":"Eckmann","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"noi260062r22","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1080\/00365521.2020.1854847","article-title":"Increased risk of inflammatory bowel disease among patients treated with rituximab in Iceland from 2001 to 2018.","volume":"56","author":"Kristj\u00e1nsson","year":"2021","journal-title":"Scand J Gastroenterol"},{"issue":"5","key":"noi260062r23","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1080\/00365521.2017.1280530","article-title":"Rituximab-induced Crohn disease.","volume":"52","author":"Varma","year":"2017","journal-title":"Scand J Gastroenterol"},{"issue":"2","key":"noi260062r25","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1080\/00365521.2016.1246605","article-title":"Validating inflammatory bowel disease (IBD) in the Swedish National Patient Register and the Swedish Quality Register for IBD (SWIBREG).","volume":"52","author":"Jakobsson","year":"2017","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"noi260062r26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/00365521.2018.1564361","article-title":"Changes in inflammatory bowel disease subtype during follow-up and over time in 44?302 patients.","volume":"54","author":"Everhov","year":"2019","journal-title":"Scand J Gastroenterol"},{"issue":"11","key":"noi260062r27","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"Pt 5","key":"noi260062r29","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1093\/brain\/124.5.962","article-title":"The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure.","volume":"124","author":"Hobart","year":"2001","journal-title":"Brain"},{"key":"noi260062r30","doi-asserted-by":"publisher","first-page":"i1981","DOI":"10.1136\/bmj.i1981","article-title":"Sparse data bias: a problem hiding in plain sight.","volume":"352","author":"Greenland","year":"2016","journal-title":"BMJ"},{"issue":"2","key":"noi260062r31","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s00415-016-8340-8","article-title":"Multiple sclerosis and inflammatory bowel diseases: a systematic review and meta-analysis.","volume":"264","author":"Kosmidou","year":"2017","journal-title":"J Neurol"},{"issue":"8954","key":"noi260062r32","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/S0140-6736(95)90013-6","article-title":"Focal white-matter lesions in brain of patients with inflammatory bowel disease.","volume":"345","author":"Geissler","year":"1995","journal-title":"Lancet"},{"issue":"1","key":"noi260062r33","doi-asserted-by":"publisher","DOI":"10.1111\/ped.15285","article-title":"Rituximab-induced Crohn disease in a child with refractory nephrotic syndrome.","volume":"64","author":"Machida","year":"2022","journal-title":"Pediatr Int"},{"issue":"3","key":"noi260062r34","doi-asserted-by":"publisher","first-page":"E41","DOI":"10.1002\/ibd.22963","article-title":"Rituximab-associated colitis.","volume":"19","author":"Bhalme","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"noi260062r35","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1186016","article-title":"Impact of anti-CD20 therapies on the immune homeostasis of gastrointestinal mucosa and their relationship with de novo intestinal bowel disease in multiple sclerosis: a review.","volume":"14","author":"Quesada-Sim\u00f3","year":"2023","journal-title":"Front Pharmacol"},{"issue":"6","key":"noi260062r36","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1007\/s00415-021-10399-8","article-title":"Discontinuation and dose reduction of rituximab in relapsing-remitting multiple sclerosis.","volume":"268","author":"Boremalm","year":"2021","journal-title":"J Neurol"},{"issue":"2","key":"noi260062r37","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/EDE.0000000000000948","article-title":"Validation of the Swedish Multiple Sclerosis Register: further improving a resource for pharmacoepidemiologic evaluations.","volume":"30","author":"Alping","year":"2019","journal-title":"Epidemiology"},{"issue":"8","key":"noi260062r38","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s10654-025-01276-z","article-title":"Completeness and generalizability of the Swedish MS register.","volume":"40","author":"Alping","year":"2025","journal-title":"Eur J Epidemiol"},{"issue":"3","key":"noi260062r39","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s10654-025-01221-0","article-title":"Diagnostic accuracy in the Swedish national patient register: a review including diagnoses in the outpatient register.","volume":"40","author":"Everhov","year":"2025","journal-title":"Eur J Epidemiol"},{"issue":"1","key":"noi260062r40","doi-asserted-by":"publisher","first-page":"5641","DOI":"10.1038\/s41467-021-25768-0","article-title":"Investigating the shared genetic architecture between multiple sclerosis and inflammatory bowel diseases.","volume":"12","author":"Yang","year":"2021","journal-title":"Nat Commun"},{"issue":"10306","key":"noi260062r41","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/S0140-6736(21)00244-0","article-title":"Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.","volume":"398","author":"McGinley","year":"2021","journal-title":"Lancet"},{"issue":"14","key":"noi260062r42","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis.","volume":"385","author":"Sandborn","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"noi260062r43","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006097.pub3","article-title":"Natalizumab for induction of remission in Crohn disease.","volume":"8","author":"Nelson","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"noi260062r44","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1093\/ecco-jcc\/jjv231","article-title":"Dimethyl fumarate reduces inflammatory responses in experimental colitis.","volume":"10","author":"Casili","year":"2016","journal-title":"J Crohns Colitis"},{"issue":"6","key":"noi260062r45","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1097\/MIB.0000000000000393","article-title":"Heritability in inflammatory bowel disease: from the first twin study to genome-wide association studies.","volume":"21","author":"Gordon","year":"2015","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"noi260062r46","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1053\/j.gastro.2019.04.016","article-title":"Environmental risk factors for inflammatory bowel diseases: an umbrella review of meta-analyses.","volume":"157","author":"Piovani","year":"2019","journal-title":"Gastroenterology"},{"key":"noi260062r28","volume-title":"The Symbol Digit Modalities Test: Manual","author":"Smith","year":"1982"},{"key":"noi260062r24","unstructured":"Swedish Neuro Registries. Multiple sclerosis. Accessed March 23, 2026. https:\/\/www.neuroreg.se\/en\/multipel-skleros\/"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2855706\/jamaneurology_kallin_2026_oi_260062_1792082257.9362.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:30:17Z","timestamp":1792679417000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2855706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":46,"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2026.3439","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,22]]}}}